Bolt Biotherapeutics
BOLT
36 hedge funds and large institutions have $17M invested in Bolt Biotherapeutics in 2024 Q2 according to their latest regulatory filings, with 5 funds opening new positions, 12 increasing their positions, 6 reducing their positions, and 6 closing their positions.
100% more repeat investments, than reductions
Existing positions increased: 12 | Existing positions reduced: 6
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
3% less funds holding
Funds holding: 37 → 36 (-1)
3.61% less ownership
Funds ownership: 62.95% → 59.34% (-3.6%)
17% less first-time investments, than exits
New positions opened: 5 | Existing positions closed: 6
68% less capital inflows, than outflows
Capital inflows: $958K | Capital outflows: $3.01M
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Tang Capital Management
San Diego,
California
|
+$387K |
| 2 |
ADAR1 Capital Management
Austin,
Texas
|
+$179K |
| 3 |
Acuitas Investments
Seattle,
Washington
|
+$111K |
| 4 |
Jane Street
New York
|
+$41K |
| 5 |
UBS Group
Zurich,
Switzerland
|
+$36.1K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
OrbiMed
New York
|
-$2.16M |
| 2 |
NM
Newtyn Management
New York
|
-$332K |
| 3 |
Renaissance Technologies
New York
|
-$238K |
| 4 |
Squarepoint
New York
|
-$109K |
| 5 |
Millennium Management
New York
|
-$64.3K |
BOLT Hedge Fund Activity: Q2 2024 in Review
36 of the 6,942 institutional investors tracked by Wall St. Rank reported a position in Bolt Biotherapeutics (BOLT) for Q2 2024, worth a combined $17M — down 49% from $33.6M a quarter earlier.
Sellers outnumbered buyers: 6 funds closed out of BOLT and 5 opened new positions — a net loss of 1 holder — while 6 trimmed existing stakes and 12 added.
The largest buyer was Tang Capital Management, adding an estimated $387K. The largest seller was OrbiMed, exiting entirely with an estimated $2.16M sold.
- 36 institutional investors held Bolt Biotherapeutics (BOLT) as of Q2 2024, down from 37 in Q1 2024.
- Funds reported $17M of Bolt Biotherapeutics stock for Q2 2024, down 49% quarter-over-quarter.
- 5 funds opened new Bolt Biotherapeutics positions in Q2 2024 and 6 closed out, a net change of -1 holder.
- The largest Bolt Biotherapeutics buyer in Q2 2024 was Tang Capital Management, an estimated $387K added.
- The largest Bolt Biotherapeutics seller in Q2 2024 was OrbiMed, an estimated $2.16M sold.
Based on aggregated 13F filings for Q2 2024.